Tag: Ocugen

Ocugen, Inc. witnessed a sharp 7% decline in its share price on Wednesday, a downturn driven by investor apprehension over ...

Biopharmaceutical firm Ocugen presents investors with a classic dilemma: promising clinical developments in gene therapy set against a backdrop of ...

While Ocugen's latest financial results showed continued losses, market participants are focusing squarely on the company's advancing clinical programs. The ...

The biotechnology firm Ocugen finds itself in a pivotal position, balancing promising clinical progress against a rapidly diminishing cash reserve. ...

The financial outlook for Ocugen has grown increasingly precarious, with the biotechnology firm's stock extending losses for five consecutive trading ...

Ocugen's latest quarterly earnings report has triggered alarm bells across the investment community. The clinical-stage biopharmaceutical company reported a significantly ...

Biotechnology firm Ocugen released its third-quarter 2025 financial results this Wednesday, presenting a complex picture of accelerating research investment alongside ...

Biotechnology firm Ocugen faces a pivotal moment this Wednesday, November 5, 2025, as it prepares to disclose its third-quarter financial ...

Biopharmaceutical firm Ocugen stands at a pivotal crossroads, with its future trajectory largely dependent on advancements within its clinical development ...

Biotechnology firm Ocugen stands at a pivotal juncture as it prepares to release third-quarter financial results on Wednesday, November 5. ...